ATM protects against oxidative stress induced by oxidized low-density lipoprotein  by Semlitsch, Michaela et al.
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a  b  s  t  r  a  c  t
Chronic  oxidative  stress  is  involved  in  the  pathogenesis  of  multiple  inﬂammatory  diseases,  including
cardiovascular  disease  and  atherosclerosis.  The  rare  autosomal  recessive  disorder  Ataxia-telangiectasia
(A-T)  is  characterized  by progressive  cerebellar  ataxia  secondary  to  Purkinje  cell  death,  immunodeﬁ-
ciency,  and  increased  cancer  incidence.  ATM,  the  protein  mutated  in A-T,  plays  a key  role  in  cellular
DNA-damage  responses.  A-T  cells  show  poor  cellular  anti-oxidant  defences  and  increased  oxidant  sensi-
tivity compared  to  normal  cells,  and  ATM  functions,  in part,  as  an  oxidative  stress  sensor.  The  oxidation  of
low-density  lipoprotein  (oxLDL)  and  its  uptake  by  macrophages  is  an initiating  step  in the  development
of  atherosclerosis.  We  demonstrate  that  oxLDL  activates  ATM  and  downstream  p21 expression  in  normal
ﬁbroblasts  and  endothelial  cells.  In ATM-deﬁcient  ﬁbroblasts  oxLDL  induces  DNA  double-strand  breaks,therosclerosis
21
olony forming efﬁciency assay
A.hy926 cells
ydrogen peroxide
micronuclei  formation  and  causes  chromosome  breaks.  Furthermore,  oxLDL  decreases  cell viability  and
inhibits  colony  formation  in  A-T  ﬁbroblasts  more  effectively  as  compared  to normal  controls.  Formation
of  oxLDL-induced  reactive  oxygen  species  is  signiﬁcantly  higher  in  A-T,  than  normal  ﬁbroblasts.  Last,
pre-treatment  of  cells  with  ammonium  pyrrolidine  dithiocarbamate,  a  potent  antioxidant  and  inhibitor
of  transcription  factor  nuclear  factor  B, reduces  oxLDL-induced  reactive  oxygen  species  formation.  Our
data indicates  that  ATM  functions  in  the  defence  against  oxLDL-mediated  cytotoxicity.. Introduction
Reactive oxygen species (ROS) are generated constantly as by-
roducts of cellular metabolism, particularly by mitochondrial
espiration [1,2]. At normal cellular concentrations, ROS play a role
n regulating cell signalling pathways and gene expression [1,2].
owever, when the production of ROS exceeds cellular antioxi-
ant capacity, damage to cellular macromolecules such as lipids,
roteins, and DNA may  occur [2,3]. To combat such damage organ-
sms have evolved anti-oxidant protective systems, including the
lutathione/glutathione disulﬁde system, superoxide dismutase,
atalase, metal chelation, and diverse repair systems that maintain
edox homeostasis [3,4]. An imbalance between ROS-generating
nd scavenging systems is called “oxidative stress” and plays a
Abbreviations: ATM, A-T mutated protein; ATM-I, ATM-kinase-inhibitor;
-T, Ataxia telangiectasia; Carboxy-H2DCFDA, 5-(and-6)-carboxy-2′ ,7′-
ichlorodihydroﬂuorescein diacetate; DCF, dichloroﬂuorescein; DSBs, DNA-double
trand breaks; LDL, low-density lipoprotein; MTT, 3-[4,5-dimethylthiazol-2-yl]-
,5-diphenyltetrazolium bromide; oxLDL, oxidized low-density lipoprotein; pATM,
hosphorylated ATM; PDTC, pyrrolidine dithiocarbamate; ROS, reactive oxygen
pecies; -H2AX, phosphorylated H2AX.
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crucial role in a variety of pathological disorders, among them car-
diovascular and neurodegenerative diseases.
Ataxia telangiectasia (A-T) is a progressive neurodegenerative
disease manifesting in early childhood. The clinical features of A-
T include progressive ataxia secondary to cerebellar Purkinje cell
death, premature aging, immunodeﬁciency, and increased cancer
risk; especially for leukaemia and lymphoma [5].  Patients with
A-T lack functioning A-T mutated protein (ATM), a member of
the phosphatidylinositol 3-kinase like family of serine/threonine
protein kinases [6]. ATM-deﬁcient cells exhibit chromosomal
instability and extreme sensitivity to DNA-double strand break
(DSB)-inducing agents, such as ionizing radiation [7].  Hence, the
most studied function of ATM is its role in response to DNA
damage. When DNA-DSBs occur, ATM is rapidly activated by
autophosphorylation at Ser1981 [8],  and in turn rapidly phospho-
rylates a number of substrates involved in DNA  replication and
repair, cell cycle checkpoint control, and apoptosis [9,10].  How-
ever, there is evidence that A-T is not only due to a defect in
DNA-DSB response, but also to a diminished control of ROS. Studies
revealed that ATM-deﬁcient cells are in a constant state of oxida-
Open access under CC BY-NC-ND license. tive stress [11]. Reichenbach and co-workers [12] reported that the
plasma of A-T patients exhibit a decreased antioxidant capacity.
Treatment with antioxidants e.g. N-acetyl-l-cysteine and tem-
pol, increased the lifespan of Atm−/− mice and tempol-treatment
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urther decreased levels of ROS and oxidative damage in thymo-
ytes of mice [13,14].  Moreover, ATM is activated by oxidants
uch as t-butyl hydroperoxide and H2O2 [15–17].  Additionally,
2O2-induced phosphorylation of ATM can be blocked by N-acetyl-
-cysteine, indicating that ATM phosphorylation is responsive to
edox imbalance [15].
ROS act as signalling intermediates in many normal cellular pro-
esses, and elevated ROS levels are linked to many pathological
onditions including neurodegenerative diseases, diabetes, cancer,
nd atherosclerosis, respectively [18]. The atherosclerotic lesion is
haracterized by an accumulation of lipids carried by lipoproteins,
uch as low-density lipoprotein (LDL). LDL becomes susceptible to
non)enzymatic oxidative modiﬁcation when retained in the artery
all [19]. These modiﬁcations make the LDL particle a potent affec-
or of cellular functions. In particular, the uptake and degradation
f oxidized LDL (oxLDL) by monocyte-derived macrophages is con-
idered the leading event in the formation of cholesterol-enriched
oam cells, which are the hallmark of fatty streaks, the earliest
ecognizable lesion of atherosclerosis [19,20].
Currently, there is no data linking ATM to the cellular responses
ollowing oxLDL exposure. However, there is indirect evidence
hat ATM may  be involved in oxLDL-induced signalling path-
ays. Apparently as a consequence of increased levels of plasma
holesterol, heterozygous ATM deﬁciency may  increase the risk
f atherosclerosis-related cardiovascular disease in humans [21].
polipoprotein E−/− (ApoE−/−) mice heterozygous in Atm developed
ccelerated atherosclerosis and multiple features of the metabolic
yndrome including glucose intolerance, hypertension, obesity and
ypercholesterolemia [22,23].  Transplantation of ApoE−/−/Atm+/+
ice with bone marrow from ApoE−/−/Atm+/+ or ApoE−/−/Atm−/−
ice revealed 80% increase in lesion severity in animals treated
ith Atm null bone marrow [24].
In the present study, we investigated the role of ATM in pro-
ection against toxicity of copper-oxLDL [25], a commonly used
xperimental model for oxidative modiﬁcation of LDL. Here we
tudied the effect of oxLDL on ATM activation and downstream
ignalling in normal ﬁbroblasts and endothelial cells. We also
nvestigated DNA damage in normal and ATM-deﬁcient ﬁbroblasts.
hird, we studied the cytotoxicity of oxLDL on normal and ATM-
eﬁcient ﬁbroblasts and last, we examined the effect of ATM status
n oxLDL-induced ROS formation in these cells.
. Materials and methods
.1. Materials
Cell culture dishes, ﬂasks and microtiterplates were from
reiner Bio-One (Frickenhausen, Germany). Dulbecco’s Modiﬁed
agle Medium (DMEM), penicillin/streptomycin and hygromycin
 were from Gibco Invitrogen (Lofer, Austria), foetal calf serum
FCS) was from PAA (Linz, Austria) and bovine serum albumin (BSA)
as from Serva (Heidelberg, Germany). Lysis buffer components
EPES, EDTA, glycerol, Triton X-100, Na4P2O7 and Na3VO4 were
rom Sigma–Aldrich (Saint Louis, MO,  USA) and NaF was  from Fluka
Buchs, Switzerland). Complete Mini protease inhibitor cocktail
ablets were from Roche Diagnostics (Mannheim, Germany). Try-
an blue stain (0.4%), NuPAGE® 4–12% Bis-Tris Gels, NuPAGE® LDS
ample buffer, NuPAGE® MOPS running buffer and nitrocellulose
embranes were from InvitrogenTM life technologies (Carlsbad,
A, USA).
Bisbenzimide (Hoechst 33258), 3-[4,5-dimethylthiazol-2-
l]-2,5-diphenyltetrazolium bromide (MTT, Thiazolyl blue),
mmonium pyrrolidine dithiocarbamate (PDTC), crystal violet and
riton X-100 were from Sigma–Aldrich (Saint Louis, MO,  USA).
arboxy-H2DCFDA (5-(and-6)-carboxy-2′,7′-dichlorodihydro-air 10 (2011) 848– 860 849
ﬂuorescein diacetate) was from Gibco Invitrogen (Lofer, Austria).
Staurosporine and the ATM-kinase-inhibitor (ATM-I, 2-morpholin-
4-yl-6-thianthren-1-yl-pyran-4-one) were from Calbiochem
(Merck, Darmstadt, Germany). BCATM Protein Assay Kit and Super
Signal West Pico Chemiluminescent substrate were from Pierce
Biotechnology, Inc. (Rockford, IL, USA). ImmobilonTM Western
Chemiluminescent HRP Substrate was from Millipore Corporation
(Billerica, MA,  USA). H2O2 was  from Herba Chemosan (Vienna,
Austria); colcemid was from Irvine Scientiﬁc (Santa Ana, CA,
USA). All other chemicals were from Roth (Vienna, Austria) or
Sigma–Aldrich (Saint Louis, MO,  USA).
The following primary antibodies were used: (i) polyclonal
rabbit phospho-ATM antibody (recognizing human ATM phos-
phorylated at Ser1981, termed pATM, R&D Systems, Minneapolis,
MN,  USA); (ii) sequence-speciﬁc polyclonal rabbit anti-ATM anti-
bodies raised against synthetic peptides corresponding to amino
acids 819–844 (Calbiochem) or 2550–2600 (Abcam, Cambridge,
U.K.) of human ATM; (iii) polyclonal rabbit anti-caspase-3 antibody
(raised against full-length caspase-3, Santa Cruz Biotechnology,
Santa Cruz, CA, USA), (iv) polyclonal anti--tubulin (Santa Cruz
Biotechnology); (v) polyclonal phospho-histone H2AX antibody
(recognizing H2AX only when phosphorylated at Ser139, termed
-H2AX, Cell Signaling Technology, Beverly, MA,  USA); (vi) rab-
bit monoclonal anti-p21 Waf1/Cip1 antibody (12D1, Cell Signaling
Technology, Beverly, MA,  USA), (vii) monoclonal anti--actin
antibody (Santa Cruz Biotechnology); (viii) monoclonal anti-Poly
(ADP-ribose) polymerase (PARP) antibody (recognizing the 116 kDa
and the 85 kDa apoptosis-related cleaved fragment, Biomol, Ham-
burg, Germany). The following secondary antibodies were used: (i)
HRP-conjugated goat anti-mouse IgG (Rockland, Gilbertsville, PA,
USA) and (ii) HRP-conjugated goat-anti-rabbit IgG (Pierce Biotech-
nology, Inc., Rockford, IL, USA).
2.2. Cell culture
WI-38 VA13 (VA13) is a SV-40-immortalized ﬁbroblast cell line
(ATCC, Rockville, MD). AT22IJE-T (AT22) is an ATM-deﬁcient SV-
40 immortalized ﬁbroblast cell line, originally established from
primary A-T ﬁbroblasts [26]. VA13 and AT22 cells were grown
in DMEM with 1 g/l glucose, 4 mM l-glutamine, 110 mg/l sodium
pyruvate and 25 mM HEPES, supplemented with 5% (v/v) FCS
and 100 U/ml penicillin/streptomycin. Human EA.hy926 endothe-
lial cells were grown in DMEM with 4.5 g/l glucose, 3.97 mM
l-glutamine and 1 mM sodium pyruvate supplemented with 10%
(v:v) FCS, 1% penicillin-streptomycin and 1 × HAT supplement [27].
All three cell lines were cultured at 37 ◦C in a humidiﬁed atmo-
sphere of 5% CO2 and 37 ◦C
2.3. Isolation and modiﬁcation of LDL
LDL was  isolated by ultracentrifugation (d = 1.027–1.063 g/ml)
from fresh human plasma, obtained from healthy volunteers
[28,29]. LDL was  sterile-ﬁltered and stored at 4 ◦C. Prior to oxi-
dation, LDL was  dialyzed overnight against PBS (10 mM;  pH 7.4)
at 4 ◦C. Oxidation of 500 g/ml LDL was performed with a ﬁnal
concentration of 30 M Cu2SO4 for 18 h. EDTA (ﬁnal concentration
2.7 mM)  terminated the reaction, the samples were saturated with
N2 and stored at 4 ◦C. Characterization of oxLDL was  performed as
described [30]. Before use, oxLDL was  sterile-ﬁltered and adjusted
to a ﬁnal protein concentration of 1 mg/ml  by dialysis under high
pressure against PBS (10 mM)  (to remove EDTA and unreacted
Cu2SO4). Lipoprotein concentrations are expressed in terms of its
protein concentration, determined by the Lowry method using BSA
as a standard.
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.4. Cell experiments for Western Blot analysis
VA13, AT22, and EA.hy926 cells were seeded in 6-well plates.
hen cells reached 70% conﬂuence, they were incubated in
erum-free DMEM overnight. Cells were treated with indicated
oncentrations of lipoproteins for the indicated times. For block-
de of the ATM-kinase signalling pathway, cells were pre-incubated
ith ATM-I [31] (10 or 30 M dissolved in DMSO) for 1 h. Cells
reated with PBS and/or DMSO served as controls. DMSO concentra-
ion did not exceed 0.01% (v/v). Alternatively, the cells were treated
ith 200 M H2O2 for 15 min  and after medium-exchange, the cells
ere incubated for further 90 min.
For protein isolation, the cells were washed twice with ice cold
BS. Cell lysis was performed on ice in 60 l lysis buffer (50 mM
EPES, 150 mM NaCl, 1 mM EDTA, 10 mM Na4P2O7, 2 mM Na3VO4,
0 mM NaF, 1% (v/v) Triton X-100, 10% (v/v) glycerol and Complete
ini protease inhibitor cocktail tablets; pH 7.4) for 10 min  [32]. The
ell lysates were scraped and insoluble cell debris was removed by
entrifugation (13,000 rpm, 4 ◦C) for 10 min.
To follow expression of -H2AX, cleavage of PARP- and
rocaspase-3, cells were pelleted by centrifugation (1000 rpm,
 min) and lysed. Protein content of cell lysates was determined
sing the BCATM Protein Assay Kit, according to the manufac-
urer’s instructions. Protein lysates (30–50 g/ml) were diluted
ith NuPAGE® LDS Sample Buffer and NuPAGE® Sample Reduc-
ng Agent (10×) and were boiled for 10 min  at 70 ◦C. Proteins were
eparated in NuPAGE® 4–12% Bis-Tris Gels and electrophoretically
ransferred to nitrocellulose membranes [33]. Membranes were
rst incubated with Tris-buffered saline Tween 20 (TBS-T, contain-
ng 5% (w/v) non-fat milk) for 2 h, before incubation with polyclonal
abbit anti-pATM antibody, polyclonal rabbit anti-ATM antibody,
olyclonal rabbit -H2AX antibody, rabbit monoclonal anti-p21
af1/Cip1 antibody, polyclonal rabbit anti-caspase-3 antibody,
onoclonal anti-PARP antibody, monoclonal anti--actin antibody
r polyclonal anti--tubulin antibody (dilution 1:500 to 1:1000 in
BS-T containing 5% (w/v) BSA) overnight at 4 ◦C. Immunoreactive
ands were visualized using HRP-conjugated goat anti-rabbit (dilu-
ion 1:50,000 in TBS-T containing 5% (w/v) non-fat milk) or goat
nti-mouse IgG (dilution 1:100,000 in TBS-T containing 5% (w/v)
on-fat milk) for 2 h, and subsequently visualized with Super Signal
est Pico Chemiluminescent substrate or ImmobilonTM Western
hemiluminescent HRP Substrate.
.5. MTT  assay
VA13 and AT22 cells were seeded in 12-well plates in DMEM
ith 5% (v/v) FCS. When cells reached 50% conﬂuence, the medium
as replaced by serum-free DMEM and the cells were incubated
vernight. Then the cells were treated with lipoproteins for the
ndicated times and at the indicated concentrations. The cells were
ashed with PBS (10 mM)  and incubated with MTT  (0.5 mg/ml;
issolved in serum-free medium) for 2 h at 37 ◦C [32]. The con-
erted dye was solubilised with acidic isopropanol (0.04 M HCl in
bsolute isopropanol). MTT  reduction was assessed by measuring
bsorption at 570 nm on a microplate reader (Victor Multilabel
ounter, Perkin-Elmer, Waltham, MA,  USA) and corrected for
ackground absorbance at 630 nm.  Each treatment was done in
riplicate and values are expressed as percentages of untreated
ells.
.6. Colony forming efﬁciency assayExponentially growing VA13, AT22, and EA.hy926 cells were
lated at a density of 1.5 × 103 cells/100 mm tissue culture dish in
he absence or presence of lipoproteins in normal growth medium.
hen indicated, the cells were preincubated with ATM-I (10 Mir 10 (2011) 848– 860
dissolved in DMSO) for 1 h before addition of lipoproteins. After
18 h of incubation, the plates were washed 3 times with PBS
(10 mM)  the medium was replaced, and the cells were cultured
for 12 more days. The cells were ﬁxed for 5 min  with methanol
and stained with crystal violet (1 g/l; dissolved in aqua dest.) and
cell clusters of 50 or more cells were counted as “colonies” under a
microscope.
2.7. Trypan blue exclusion assay
VA13 and AT22 cells were seeded in 6-well plates until 50%
conﬂuence was  reached. After overnight serum-starvation, cells
were incubated with indicated concentrations of lipoproteins. At
the indicated times, the cells were washed with PBS (10 mM),
trypsinized and resolved in serum-free DMEM.  The cell suspen-
sion was mixed with 1:1 (v/v) with 0.4% (w/v) Trypan blue stain.
Viable cells, identiﬁed by a clear cytoplasm, were counted using
CountessTM cell counting chamber slides and the CountessTM Auto-
mated Cell Counter (InvitrogenTM life technologies, Carlsbad, CA,
USA).
2.8. Micronucleus assay and staining of nuclei with bisbenzimide
VA13 and AT22 cells were seeded in 6-well plates on glass
cover slips and cultured in normal growth medium. When cells
reached 50% conﬂuence, cells were serum-starved overnight and
incubated with 100 g/ml lipoprotein for 16 h. Cells were washed
with PBS (10 mM)  and ﬁxed with 90% (v/v) methanol for 5 min.
Staining of nuclei was  performed with 0.5 g/ml bisbenzimide
(Hoechst 33258). Cells on glass cover slips were incubated with
the ﬂuorescence-dye for 30 min  in the dark, washed with aqua
dest., air dried and mounted with glycerol. Micronuclei were scored
and cell images recorded with an FSX100 Box-Type Fluorescence
Imaging Device (Olympus Corporation, Tokyo, Japan). Before scor-
ing the micronuclei, all slides were randomised and coded. The
number of micronuclei was  determined by counting 500 cells/slide.
The criteria for scoring micronuclei were adapted from refer-
ences [34,35]; each treatment was  done in triplicate. Values are
expressed as percentages of the number of micronuclei in untreated
cells.
2.9. Estimation of chromosome breaks
Logarithmically growing VA13 and AT22 cells were plated in
100 mm tissue culture plates. When the cells reached 50% con-
ﬂuence, they were treated with 30 g/ml lipoproteins for 8 h. To
arrest the cells in metaphase, colcemid (100 ng/ml) was added
for 4 h [36]. The cells were washed with PBS and trypsinized.
The reaction was  stopped with DMEM and cells were pelleted
5 min  at 500 × g. Then, the cells were resuspended in 0.075 mM
KCl and incubated for 15 min  at 37 ◦C. Two hundred microliter
of Carnoy’s ﬁxative (methanol:glacial acetic acid, 3:1 [v/v]) was
added; cells were gently mixed and pelleted (5 min, 500 × g). The
supernatant was removed, cells were twice gently mixed with
5 ml  of Carnoy’s ﬁxative and pelleted (5 min  at 500 × g) again. Cell
lysates were dropped on glass slides and dried for 30 min at 90 ◦C.
Chromosomes were stained with Giemsa. For scoring chromosome
breaks, 5000 individual chromosomes/treatment were observed
under oil immersion microscopy. Each treatment was done in
triplicate.
2.10. Measurement of ROSThe intracellular generation of ROS was  measured using
carboxy-H2DCFDA. H2DCFDA is deacetylated by esterases to non-
ﬂuorescent dichloroﬂuorescein, which is converted to ﬂuorescent
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Fig. 1. Time-dependent phosphorylation of ATM in normal ﬁbroblasts by oxLDL and
inhibition of ATM-activation: (A) VA13 cells were incubated with 100 g/ml oxLDL
at  indicated times. (B) VA13 cells were preincubated with 10 M of the ATM-kinase-
inhibitor (ATM-I) for 1 h followed by treatment with 100 g/ml lipoprotein for
90  min. As positive controls, cells were treated with 200 M H2O2 for 15 min; after
medium exchange the cells were incubated for another 90 min (105*). Cell lysates
were collected; proteins were subjected to SDS-PAGE and transferred to nitrocel-M. Semlitsch et al. / DN
ichloroﬂuorescein (DCF) by ROS. VA13 and AT22 cell were cul-
ured in 6 well plates in DMEM containing 5% FCS. Fifty % conﬂuent
ells were serum-starved overnight and incubated with indicated
oncentrations of lipoproteins for 5, 12 or 24 h. When indicated,
ells were pre-treated with PDTC for 30 min  (1 mM;  dissolved in
qua dest.). For inhibition of ATM, cells were preincubated with the
TM-I for 1 h before addition of lipoproteins. DMSO concentration
id not exceed 0.01% (v/v). After indicated times, the medium was
spirated and 10 M carboxy-H2DCFDA, dissolved in PBS (10 mM),
as added to the cells [37]. Cells were incubated for another 30 min
t 37 ◦C. To terminate the reaction, cells were kept on ice and
ashed with ice-cold PBS. Cell lysis was performed with 3% (v/v)
riton X-100 in PBS on a rotary shaker (1350 rpm; Heidolph Instru-
ents, Schwabach, Germany) at 4 ◦C (in the dark) for 30 min. To
nsure complete solubilisation of DCF, 50 l absolute ethanol was
dded and the plates were shaken for a further 15 min  [37]. The cell
ysates were transferred to microfuge tubes and cellular debris was
emoved by centrifugation (13,000 rpm, 4 ◦C, 10 min). One hun-
red microliter of the supernatant was transferred into 96-well
icrotiter plates and ﬂuorescence was measured on a Victor Mul-
ilabel Counter (Perkin-Elmer, Waltham, MA,  USA) with excitation
t 485 nm and emission at 540 nm.  All steps concerning carboxy-
2DCFDA were performed under light-protected conditions. The
rotein content of the cell lysates was determined using an aliquot
f the supernatant and the BCATM Protein Assay Kit according to
he manufacturer’s instructions.
.11. Image analysis for generation of intracellular ROS
VA13 and AT22 cells were seeded in 6-well plates, grown to
0% conﬂuence, and incubated with serum-free DMEM overnight.
here indicated, cells were pre-treated with 1 mM PDTC (dissolved
n aqua dest.) for 30 min. Cells were incubated with 100 g/ml
ipoprotein for 5 or 12 h. Carboxy-H2DCFDA (10 M,  dissolved in
0 mM  PBS) was added to the cells and plates were incubated for
urther 30 min  at 37 ◦C. To terminate the reaction, dishes were put
n ice and cells were washed with PBS. For observation of the
ells under a ﬂuorescence microscope, 100 l PBS was  added to
ach well. The cells were observed and photographed using an
nverted microscope (Nikon Eclipse TE 2000-U; Nikon Instruments,
elville, NY, USA) with a green ﬂuorescent ﬁlter and the NIS Ele-
ents BR 2.10 software for image acquisition. To allow comparison
etween images, all images were acquired at the same exposure
ime (600 ms).
.12. Statistical analysis
Data are presented as means ± standard deviation (SD). Two-
ay ANOVA or t-test statistical analyses were performed using
rism 5 software (Graphpad Software, La Jolla, CA, USA). In ANOVA
nalysis, Bonferroni posttest was used for all pair wise compar-
sons of the means of all experimental groups. Values (p < 0.05) were
onsidered signiﬁcant.
. Results
.1. ATM is activated by oxLDL
Previous reports performed with various cell lines revealed that
ependent on the stimulus, activation of ATM occurs between
5 and 480 min  [38,39].  We  here show that VA13 cells (ATM+/+)
xhibited either no (data not shown) or sometimes basal pATM
xpression (Fig. 1A). OxLDL increased pATM levels in a time-
ependent manner reaching a maximum after 90 min  (Fig. 1A).
he immunoreactive pATM signal decreased to baseline levels afterlulose membranes. Western Blot experiments were performed using anti-pATM
as primary antibody. -Tubulin was used as loading control. One representative
experiment out of three is shown.
300 min. H2O2 a known activator of ATM [15,40], resulted in efﬁ-
cient phosphorylation of ATM in VA13 cells but not in AT22 cells
(termed ATM−/−). Densitometric evaluation of immunoreactive
pATM bands revealed that H2O2-mediated induction is approxi-
mately 25% higher after 90 min compared with oxLDL-mediated
induction. Although two different polyclonal antibodies were used
to follow total ATM expression, immunoreactive -tubulin was
found to be more precise and reliable as loading control. Fig. 1B
demonstrates that LDL sometimes tended to phosphorylate ATM in
VA13 cells, however, only to levels in between 5 and 10% compared
to oxLDL. Fig. 1B further shows that oxLDL-induced phosphoryla-
tion of ATM was  completely abrogated by ATM-I (Fig. 1B).
3.2. ATM expression moderates the toxic effect of oxLDL
Cells that fail to repair damaged DNA before entering mitosis
may exhibit chromosomal strand breaks, leading to disruption in
subsequent cell cycles resulting in a defective colony formation
[41]. As ATM plays an important role in the recognition and sig-
nalling of DNA damage [42], we  studied whether the lack of ATM
affects the clonogenic survival of cells. Fig. 2A shows that oxLDL,
but not LDL, caused a dose-dependent inhibition of colony forma-
tion in VA13 and AT22 cells. However, at protein concentrations
higher than 3-g  oxLDL/ml, colony formation in AT22 cells was
signiﬁcantly (p < 0.001) reduced compared to VA13 cells.
To support our observation, that the presence of ATM affects
the clonogenic survival, ATM-activation in VA13 cells was inhib-
ited before oxLDL treatment. Fig. 2B shows that ATM-I reduced
colony formation in VA13 cells to levels found in AT22 cells when
treated with oxLDL. Again, LDL did not alter colony formation when
compared to untreated control cells.
3.3. ATM and cell viability in the presence of oxLDL
Next, mitochondrial function and cell viability of normal and
ATM-deﬁcient cells were investigated using two different assay
systems. The MTT-test forms blue formazan crystals that are
reduced by mitochondrial dehydrogenase in living cells [43]. OxLDL
decreased cell viability in VA13 and AT22 cells in a time- (Fig. 3A)
and concentration-dependent manner (Fig. 3B). AT22 cells are more
sensitive to oxLDL exposure than VA13 cells (Fig. 3). LDL had no
852 M. Semlitsch et al. / DNA Repair 10 (2011) 848– 860
Fig. 2. OxLDL alters colony-forming efﬁciency in normal and ATM-deﬁcient ﬁbroblasts: (A) Exponentially growing VA13 and AT22 cells were plated at a density of
1.5  × 103 cells/100 mm dish in DMEM with increasing lipoprotein concentrations. After 18 h, the medium was  replaced and cells were cultured for 12 days. (B) 1.5 × 103
cells of VA13 and AT22 cells, plated on a 100 mm dish, were pre-incubated with 10 M ATM-I for 1 h before addition of 30 g/ml lipoprotein. After 18 h the medium was
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untreated cells). **p < 0.01 and ***p < 0.001 (signiﬁcant difference between VA13 an
dverse effect on the viability of either cell type. Next, cell survival
as measured using the Trypan blue exclusion assay. Incubation
f VA13 and AT22 cells with oxLDL up to 24 h decreased the num-
er of living cells in a time-dependent manner up to 30% (Fig. 4A).
gain, oxLDL was more toxic to AT22 cells at all times, com-
ared to VA13 cells. LDL (used as control) had no effect on cell
he survival of both cell lines. To visualize nuclear changes after
reatment with lipoproteins, VA13 and AT22 cells were stained
ith Hoechst 33258 and ﬂuorescence intensity was  checked. Con-
rol and LDL-treated cells exhibited diffuse chromatin staining
Fig. 4B). However, exposure of VA13 cells to oxLDL led to mor-
hological changes, such as areas of condensed chromatin and
hrunken nuclei. In contrast, AT22 cells treated with oxLDL exhib-
ted a decrease in size and number of nuclei, but no chromatin
ondensation.
.4. OxLDL induces DNA double strand breaks in A-T cells
ATM primarily responds to DSBs [7].  Since phosphorylation of
he histone H2AX (termed -H2AX) is a sensitive cellular indicator
or the presence of DNA-DSBs [44,45],  the effect of lipoproteins on
2AX phosphorylation via ATM was studied. Fig. 5A shows that
xposure of VA13 and AT22 cells to oxLDL led to formation of
mmunoreactive -H2AX only in AT22 but not in VA13 cells. Also,
ime-dependent incubation of both cell lines with oxLDL, but not
DL, conﬁrmed the presence of immunoreactive -H2AX after 16 h
nly in AT22 cells (Fig. 5B). Since the MTT  assay demonstrated that
xLDL is toxic to VA13 and AT22 cells (Fig. 4A), PARP cleavage and
ctivation of procaspase 3 (two hallmarks of apoptosis) were inves-lonies were ﬁxed, stained with crystal violet and colonies consisting of groups of
pared to untreated cells, set as 100%). Values represent the means ± SD (n = 5). UT
2 cells).
tigated. After 16 h of oxLDL exposure neither PARP cleavage nor
procaspase 3 processing was  observed in either cell type (Fig. 5A).
Following time-dependent incubation of cells with lipoproteins up
to 24 h, neither LDL nor oxLDL promoted PARP cleavage or activa-
tion of caspase 3 (Fig. 5B).
To assess whether the immunoreactive -H2AX signal corre-
lates with micronucleus formation following oxLDL exposure, and
to investigate a possible clastogenic effect of oxLDL, the in vitro
micronucleus technique was employed. Micronuclei arise during
cell division and contain chromosome breaks lacking centromeres
and/or whole chromosomes, and are unable to travel to the spindle
poles during mitosis [34]. Our ﬁndings show that oxLDL-treated
AT22 cells displayed a signiﬁcantly higher micronuclei number
compared to similarly treated VA13 cells (Fig. 6A). Treatment of
both cell lines with LDL did not alter the micronuclei number when
compared to untreated controls. Since micronuclei formation is a
sign of chromosomal damage, the number of chromosomal breaks
was  further counted in VA13 and AT22 cells in the absence or
presence of lipoproteins. Cells lacking ATM exhibited a slightly
higher number (although statistically not signiﬁcant) of chromoso-
mal  breaks in untreated cells compared to VA13 (Fig. 6B). However,
oxLDL signiﬁcantly (p < 0.001) increased chromosomal breaks in
both cell lines. In VA13 cells, the number of chromosomal breaks
after 8 h increased up to 30. In AT22 cells the number of chro-
mosomal breaks increased up to 42. Fig. 6B further shows that
the number of oxLDL-induced chromosomal breaks in AT22 cells
are signiﬁcantly (p < 0.001) higher when compared to VA13 cells.
Treatment of VA13 and AT22 cells with LDL was  without effects on
chromosomal breaks when compared to untreated cells (Fig. 6B).
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Fig. 3. Time- and concentration-dependent effect of lipoproteins on cell viability of in normal and ATM-deﬁcient ﬁbroblasts using the MTT  assay: (A) VA13 and AT22 cells
were  treated with 100 g/ml lipoprotein for indicated times. (B) VA13 and AT22 were exposed to 3, 30 and 100 g/ml lipoprotein for 18 h. MTT reduction was assessed
at  570 nm on a microplate reader and values were corrected for background absorbance at 630 nm.  Values are expressed as percentages of untreated cells. The data are
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.5. PDTC scavenges oxLDL-induced elevated ROS levels in A-T
ells
ATM-deﬁcient cells are in a constant state of oxidative stress
nd may  exhibit diminished antioxidant capacity [11,46]. We
how that AT22 cells exhibited approx. 1.5-fold higher ROS lev-
ls when compared to VA13 cells (Fig. 7A). Incubation of cells
ith oxLDL further increased ROS levels in VA13 and AT22 in a
ime-dependent manner. ROS formation induced by oxLDL was
igniﬁcantly (p < 0.001) higher in AT22 cells at 5 and 12 h com-
ared to VA13 cells. After 24 h, ROS levels were also higher in
T22 cells, although not statistically signiﬁcant. LDL did not affect
OS levels in VA13 or AT22 cells (Fig. 7B). Treatment of cells
ith increasing concentrations of oxLDL for 5 h led to a dose-
ependent increase of ROS, which is signiﬁcantly higher (up to
-fold compared with untreated cells) in AT22 cells compared
o VA13 cells (Fig. 7C). Findings obtained with the DCFDA/DCF
ssay (Fig. 7), i.e. incubation of cells with lipoproteins and sub-
equent ROS measurements, were conﬁrmed using ﬂuorescence
icroscopy (Fig. 7D). AT22 cells exposed to oxLDL exhibited
igher ﬂuorescence intensity when compared to untreated or
DL-treated cells. In line with data shown in Fig. 7B, a slight
ncrease in ﬂuorescence-intensity could also be observed in oxLDL-
reated VA13 cells when compared to untreated or LDL-treated
ells.
To conﬁrm, that ATM regulates ROS formation, cells were pre-
reated with ATM-I before incubation with oxLDL. DCF ﬂuorescence
easurements revealed that inhibition of ATM led to signiﬁcantly
p < 0.01) higher levels of basal ROS in VA13 cells but also when
ells were treated with oxLDL (Fig. 7E). No signiﬁcant difference in
OS levels were found in oxLDL-treated AT22 cells in the absence5 and ***p < 0.001 (signiﬁcant difference between VA13 and AT22 cells).
or presence of ATM-I indicating that the compound per se did not
alter ROS formation.
To scavenge ROS, cells were pre-incubated with PDTC, a potent
antioxidant and suppressor of transcription factor nuclear factor
B [47], prior to incubation with oxLDL. PDTC effectively reduced
oxLDL induced ROS-formation in AT22 and VA13 cells to basal lev-
els (Fig. 8A). Also ﬂuorescence microscopy technique showed less
ﬂuorescence intensity in oxLDL-treated cells after preincubation
with PDTC for 1 h (Fig. 8B).
3.6. OxLDL induces p21 via an ATM-dependent pathway
Activation of the ATM-kinase may  promote induction of p53
[10]; stabilized p53 serves as a transcription factor and stimulates
expression of the cyclin-dependent kinase inhibitor p21 [48]. Fig. 9
shows oxLDL-mediated induction of p21 in VA13 (but not in AT22)
cells. Inhibition of the ATM-kinase activity in VA13 cells reduced
oxLDL-induced expression of immunoreactive p21 to baseline lev-
els.
In the series of experiments, we have tested whether oxLDL-
mediated expression of pATM and subsequent induction of p21 is
also operative in cells other than ﬁbroblast. These data indicate that
induction of pATM by oxLDL in endothelial cells occurs in a time-
dependent manner (Fig. 10A) similar as found in VA13 ﬁbroblasts
(Fig. 1A); densitometric evaluation of immunoreactive pATM bands
revealed a 1.7-fold induction after 90 min  (Fig. 10A). Furthermore,
pre-incubation of endothelial cells with ATM-I did not only inhibit
phosphorylation of the ATM-kinase (Fig. 10B) but also down regu-
lated time-dependent expression of p21 (Fig. 10C) as well as colony
formation of oxLDL-treated cells (Fig. 10D).
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Fig. 4. Time-dependent effect of lipoproteins on cell viability of normal and ATM-deﬁcient ﬁbroblasts using the Trypan blue exclusion assay: (A) AT22 and VA13 cells were
cultured in the presence of 100 g/ml lipoprotein at indicated times. Cells were stained with Trypan blue and viable cells were counted. Each time point represents the mean
value  ± SD of three experiments performed in triplicates. (B) Fluorescence images of Hoechst 33258-stained VA13 and AT22 cells after treatment with 100 g/ml lipoprotein
for  16 h. Untreated cells were used as controls. Aggregated and fragmented chromatin appears as bright areas. One representative experiment out of four is shown.
Fig. 5. OxLDL induces phosphorylation of H2AX in ATM-deﬁcient ﬁbroblasts: AT22 and VA13 cells were treated (A) with 100 g/ml oxLDL for 16 h or (B) with 100 g/ml
lipoprotein at indicated times. VA13 cells were treated with 1 M staurosporine (St) for 4 h to induce phosphorylation of H2AX and apoptosis. Cells were lysed and protein
lysates were subjected to Western Blot analysis following SDS-PAGE. Polyclonal anti--H2AX was used as primary antibody. Membranes were then stripped and incubated
with  anti-PARP and anti-caspase-3 antibody as primary antibodies. -Actin served as a loading control.
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Fig. 6. OxLDL promotes formation of micronuclei and chromosomal breaks in AT22 ﬁbroblasts: (A) VA13 and AT22 cells were incubated with 100 g/ml lipoprotein for 16 h.
Cells  were ﬁxed with methanol and stained with Hoechst 33285. Numbers of micronuclei/500 cells were counted using a ﬂuorescence microscope. The arrow indicates a typical
micronucleus formation in AT22 cells. Data are expressed as percentage of untreated cells and represent the means ± SD (n = 6). (B) VA13 and AT22 cells were incubated
w osom
o treat
c
4
g
m
a
i
g
g
m
t
c
l
o
t
a
m
b
m
c
o
b
s
a
T
s
a
m
tith  30 g/ml lipoprotein for 8 h. Metaphase preparations were made and chrom
bservations performed under oil immersion microscopy done in triplicate. UT (un
ells).
. Discussion
A-T, an autosomal recessive disorder resulting from ATM
ene mutation, is characterized by a high incidence of lymphoid
alignancies, neurodegeneration, immunodeﬁciency, premature
ging, elevated radiosensitivity, and genomic instability. Genomic
nstability is characterized by chromosome breaks, chromosome
aps, translocations, and aneuploidy [42,49].  Recent ﬁndings sug-
ested that DNA damage links mitochondrial dysfunction to the
etabolic syndrome and atherosclerosis, indicating that preven-
ion of mitochondrial dysfunction may  represent a novel target of
ardiovascular disease [23]. Basically, mitochondrial dysfunction is
inked to ATM-heterozygosity [50,51] and results in an imbalance
f ROS [23]. As ROS levels are tightly coupled with inﬂamma-
ory diseases e.g. atherosclerosis, increased ROS levels in ATM−/−
nd ATM+/− cells may  be due to alterations in cellular defence
echanisms and possibly due to cellular dysfunction induced
y modiﬁed/oxidized (lipo)proteins. Among different lipoprotein
odiﬁcations, the oxidation of LDL by transition metals such as
opper ions represents a suitable experimental approach to mimic
xidative modiﬁcations of LDL in vivo [19,25,52,53].  OxLDL has
een reported to participate in the development of atherosclero-
is primarily by promoting vascular cell growth [54–57].  OxLDL is
 potent proinﬂammatory chemoattractant for macrophages and
-lymphocytes. OxLDL is also cytotoxic for endothelial cells and
timulates them to release soluble inﬂammatory molecules. In
ddition, oxLDL has turned out to be highly immunogenic and pro-
otes changes in cell cycle protein expression, and subsequent
ranslocation and activation of transcription factors [58,59]. Theseal breaks were counted. Each data point represents 5000 individual chromosome
ed cells). *p < 0.05 and ***p < 0.001 (signiﬁcant difference between VA13 and AT22
events help to perpetuate a cycle of vascular inﬂammation and
lipid/(lipo)protein dysregulation within the artery wall and also
may create a cellular pro-thrombotic state that complicates later
stages of atherosclerosis [59].
In the present study, we  demonstrated that oxLDL, known to
generate oxidative stress in the vascular system [19,25],  induced
phosphorylation of ATM and downstream activation of p21 in
ﬁbroblasts and endothelial cells. The immunoreactive pATM sig-
nal induced by oxLDL was  almost comparable to levels induced
by H2O2. ATM-deﬁcient cells are extremely sensitive to the toxic
effects of H2O2, nitric oxide radical, and t-butyl hydroperoxide,
respectively [38,60]. To obtain information on sensitivity of ATM-
null ﬁbroblasts to oxLDL, several different cytotoxicity assays were
employed (Figs. 2–4). All three assays demonstrated that in com-
parison to wild-type cells, ATM-deﬁcient ﬁbroblasts are more
sensitive to oxLDL treatment – indicating that ATM-expression
lessens oxLDL-mediated toxicity. However, ﬁbroblasts lacking ATM
were more sensitive to oxLDL-treatment in the colony-forming
assay, than was observed in the short-term culture assays (MTT-
and Trypan blue exclusion assay). This is probably due to defec-
tive cell cycle response in A-T cells, as these cells may replicate
their DNA despite having unrepaired DNA breaks. Both, the MTT
and the Trypan blue exclusion assay, and the appearance of con-
densed chromatin, demonstrated that oxLDL exhibited mild toxic
effects on VA13 cells, with PARP cleavage and caspase 3 activa-
tion not being detected. We  assume that due to the mild toxic
effects of oxLDL in normal ﬁbroblasts, ATM induction triggers
an activation of cell cycle checkpoints and not apoptotic cascade
activation.
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Fig. 7. Time- and concentration-dependent intracellular ROS levels in normal and ATM-deﬁcient ﬁbroblasts: (A) To measure basal intracellular ROS  levels, AT223 and VA13
cells  were loaded for 30 min  with 10 M carboxy-H2DCFDA in the absence of agonists. The DCF ﬂuorescence counts detected with VA13 cells were set 100%. (B) Cells were
incubated with 100 g/ml lipoprotein for indicated times and ROS levels were measured as described above. The DCF ﬂuorescence counts in untreated cells were set 100%.
(C)  Cells were incubated with indicated concentrations of oxLDL for 5 h before ROS measurements. The DCF ﬂuorescence counts in untreated cells were set 100%. (D) Cells
were  incubated with 100 g/ml lipoprotein for 12 h and loaded with 10 M carboxy-H2DCFDA for 30 min. DCF ﬂuorescence was observed under ﬂuorescence microscope.
(E)  Cells were pre-treated with 10 M ATM-I for 1 h prior to incubation with 100 g/ml lipoprotein for 5 h. Then ROS levels were measured. The DCF ﬂuorescence counts in
untreated cells were set 100%. (A, B, C, and E) DCF ﬂuorescence values were normalized to cell protein content. Data are expressed as mean ± SD (n = 6). UT (untreated cells).
**p  < 0.01 and ***p < 0.001 (signiﬁcant difference between VA13 and AT22 cells).
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Fig. 8. PDTC protects against ROS-generation induced by oxLDL in ATM-deﬁcient ﬁbroblasts: (A) AT22 and VA13 cells were incubated with PDTC for 1 h and treated with
100  g/ml oxLDL for 5 h. Levels of endogenous ROS were calculated by measuring DCF ﬂuorescence. Results are expressed as ﬂuorescence intensity as % of control and
represent the means ± SD (n = 6) ***p < 0.001. (B) Fluorescence microscopy of AT22 and VA13 cells stained with carboxy-H2DCFDA. Cells were pre-treated with 1 mM PDTC
for  1 h and incubated with 100 g/ml oxLDL for 5 h.
Fig. 9. ATM-kinase-dependent activation of p21 in VA13 ﬁbroblasts by oxLDL: AT22 and VA13 cells were incubated with 100 g/ml oxLDL at indicated times in the absence
or  presence of 10 M ATM-I (preincubated for 1 h). Cell lysates were subjected to SDS-PAGE, proteins were transferred to nitrocellulose and membranes were incubated
with  anti-p21 Waf1/Cip1 as the primary antibody. -Actin was used as loading control. One representative experiment out of two is shown.
Fig. 10. ATM-kinase activation and induction of p21 in endothelial cells by oxLDL: EA.hy926 cells were incubated with 100 g/ml oxLDL (A, B, C) or LDL (B) at indicated
times  or for 90 min  in the absence or presence of 10 M (C) or 10 and 30 M (B) ATM-I (preincubated for 1 h). As positive controls, cells were treated with 200 M H2O2 for
15  min; after medium exchange the cells were incubated for another 90 min (105*) (A). Cell lysates were subjected to SDS-PAGE, proteins were transferred to nitrocellulose
and  membranes were incubated with anti-pATM (A, B) or anti-p21 (C) as primary antibody. -Tubulin (A, B) or -actin (C) was used as loading control. One representative
experiment out of two is shown. (D) Colony forming efﬁciency of EA.hy926 cells treated with 30 g/ml lipoprotein in the absence or presence of 10 M ATM-I was performed
exactly as described in Fig. 2B. Data are given as number of colonies (as percentage compared to untreated cells, set as 100%). Values represent the means ± SD (n = 3). UT
(untreated cells). **p < 0.01 and ***p < 0.001.
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OxLDL-mediated toxicity was signiﬁcantly higher in ATM-
eﬁcient ﬁbroblasts. We  assume that these cells (defective in G1,
 and G2 checkpoint functions [16,61]) are unable to respond
dequately to oxLDL-induced oxidative stress and/or DNA dam-
ge. The result is oxLDL hypersensitivity and eventual cell death.
o conﬁrm this hypothesis the effect of oxLDL on DNA damage
as investigated. A very early step in the response to DNA-DSBs
s the appearance of immunoreactive -H2AX [44]. -H2AX is
n essential component for the recruitment and accumulation of
NA repair proteins to sites of DSB damage, including 53BP1,
RCA1, RAD51 and MDC1 and the MRE11/RAD50/NBS1 complex
62]. In the presence of DNA-DSBs, H2AX is rapidly phospory-
ated by ATM [63]. However, H2AX can also be phosphorylated by
ther members of the phosphatidylinositol 3-kinase family, includ-
ng DNA-dependent protein kinase and the ATM-and Rad3-related
rotein kinase [64,65]. We  found that following oxLDL exposure
mmunoreactive -H2AX was present only in ATM-deﬁcient AT22,
ut not in VA13 cells. As oxLDL leads to ATM-phosphorylation in
A13 cells, this data indicates that ATM is activated by oxLDL in the
bsence of DNA-DSBs. ATM is a key player in DSBs responses, being
ctivated by these breaks and phosphorylating key down-stream
roteins, leading to cell cycle checkpoint arrest and/or apoptosis
66]. However, lack of ATM causes not only a defective response
o DNA-DSBs, but also a defect in regulating cellular responses to
xidative stress [7,17].  Our ﬁndings are consistent with a recent
tudy [17], demonstrating that ATM activation induced by H2O2
ccurs in the absence of DNA damage. The observation that oxLDL-
ependent H2AX phosphorylation was only observed in ATM−/−
ells suggested that another member of the phosphatidylinositol
-kinase family is likely to be involved in this pathway. Further-
ore, the appearance of -H2AX in ATM-deﬁcient cells makes it
easonable to assume that ATM protects against oxLDL-induction
f DNA-DSBs. Increased formation of micronuclei and a higher
umber of chromosomal breaks in oxLDL-treated AT22 cells (as
ompared to VA13 cells) gives further support to this hypothesis.
Accumulating evidence suggests that oxidative stress is
nvolved in the pathogenesis of A-T. Loss of ATM leads to increased
xidative damage to proteins and lipids and many cell-types, such
s bone marrow stem cells and thymocytes of mice, exhibit elevated
evels of ROS [7,67–69]. In line with these observations, we  detected
ncreased basal levels of ROS in ATM-deﬁcient ﬁbroblasts. Treat-
ent with oxLDL further ampliﬁed ROS formation in ATM-deﬁcient
nd normal ﬁbroblasts. Also, oxLDL-induced ROS formation was
igniﬁcantly higher in ATM-deﬁcient AT22 cells and in response to
harmacological inhibition of ATM in VA13 cells. This indicates that
TM protects from oxLDL-induced intracellular ROS production
nd that ATM expression may  play a critical role in cell function and
urvival in atherosclerosis. Most importantly, cellular and molecu-
ar responses of ﬁbroblasts from atherosclerosis patients towards
onizing radiation, activating the ATM-stress response, are similar
o those observed from cells obtained from A-T patients [70]. The
xLDL-induced elevation of ROS, but no signs of DNA damage, in
ormal ﬁbroblasts, conﬁrmed the hypothesis, that not DNA-DSBs
ut ROS triggers oxLDL-induced activation of ATM. These obser-
ations parallel recent data [71] where ROS potently and rapidly
ctivates ATM in the cytoplasm suggesting that mechanisms other
han DNA-DSBs in the nucleus are operative to promote activation
f ATM.
Administration of antioxidants to Atm−/− mice exhibited a
ariety of beneﬁcial effects, including extended lifespan, reduced
umorigenesis and improvement of motor deﬁcits [13,14,72].
re-treatment of ATM-deﬁcient cells with N-acetyl-l-cysteine
ttenuated ROS formation and blocked activation of ATM
15,17,67]. Due to redox cycling, N-acetyl-l-cysteine is able to
educe Cu2+- to Cu+-ions that can promote metal-catalyzed lipid
eroxidation in vitro [73]. However, we here used PDTC to scav-
[
[ir 10 (2011) 848– 860
enge oxLDL-induced formation of ROS. PDTC induces glutathione
synthesis in endothelial cells and suppresses the activation of tran-
scription factor nuclear factor B [73,74]. Most importantly, PDTC
possesses metal-chelating properties and therefore, generation of
free Cu2+-ions, recently reported to activate ATM in murine neu-
roblastoma cells and human HeLa cells [75], can be excluded under
our experimental conditions. Here we show that PDTC is able to
diminish formation of intracellular ROS induced by oxLDL in both,
normal and ATM-deﬁcient cells almost to basal levels.
In conclusion, we demonstrated that ATM is involved in oxLDL-
mediated signalling. OxLDL-mediated activation of ATM occurs via
intracellular formation of ROS and not via induction of DNA-DSBs.
We propose that under conditions of ATM deﬁciency, oxLDL-
dependent ROS production induces DNA damage chromosomal
instability and cell death. As a consequence, H2AX, required for the
repair mechanisms of ROS-induced DNA damage in ATM-deﬁcient
cells [76], is phosphorylated. Furthermore, we demonstrated that
PDTC acts as a potent antioxidant against oxLDL-induced ROS
formation. Our data enforce the role of ATM as a sensor of
oxidative stress that could be important for protection against
oxLDL-mediated cellular toxicity. Therefore, the ability of oxLDL
to activate the ATM pathway may represent a critical adaptive
response to maintain cell viability at sites of vascular inﬂammation
and atherosclerosis.
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